Table 2 Treatment parameters.
Parameters | Number of patients (n = 75) | |
|---|---|---|
Absolute (n) | Relative (%) | |
Irradiation in primary vs recurrent treatment | ||
RT as primary treatment | 66 | 88.0 |
RT only | 49 | 74.2 |
Resection prior to RT | 8 | 12.1 |
Systemic therapy prior to RT | 2 | 3.0 |
Rituximab | (1) | |
R-CHOP | (1) | |
Concurrent Rituximab to RT | 4 | 6.0 |
Systemic therapy sequentially given post RT | 1 | 1.5 |
Bendamustin/rituximab | ||
Resection and systemic therapy prior to RT | 2 | 3.0 |
Resection → Rituximab | (1) | |
Resection → R-CVP | (1) | |
RT as recurrent treatment | 9 | 12.0 |
Systemic therapy prior to RT | 6 | 66.7 |
Resection prior to RT | 3 | 33.3 |
Single dose per fraction (Gy) | ||
1.5 | 4 | 5.3 |
1.8 | 33 | 44.0 |
2.0 | 38 | 50.7 |
Median (range) | 2.0 Gy (1.5–2.0 Gy) | |
Total dose of radiation therapy (Gy) | ||
< 24 Gy | 1 | 1.3 |
24–36.0 Gy | 46 | 61.3 |
> 36.0 Gy | 28 | 37.3 |
Median (range) | 30.6 Gy (16–45 Gy) | |
Technique of irradiation | ||
2D—RT | 10 | 13.3 |
3D—RT | 63 | 84.0 |
VMAT | 2 | 2.7 |
Energy beam | ||
6 MeV | 48 | 64.0 |
> 6 MeV | 27 | 36.0 |
Radiation field | ||
IFRT | 43 | 57.3 |
ISRT | 32 | 42.7 |
Target volume | ||
Extra nodal regions | 40 | 53.3 |
Inguinal or femoral lymph node region | 18 | 24.0 |
Cervical of supraclavicular LN region | 10 | 13.3 |
Other LN region | 7 | 9.3 |
